RJFSA
INMB icon

Raymond James Financial Services Advisors’s INmune Bio INMB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.99M Buy
369,438
+141,904
+62% +$1.01M ﹤0.01% 1725
2024
Q2 		$2.01M Buy
+227,534
New +$2.24M ﹤0.01% 1667

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial Services Advisors's INMB Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its INmune Bio (INMB) stake by 62% in Q3 2024, buying an estimated $1.01M and bringing the position to 369,438 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Raymond James Financial Services Advisors first reported a position in INMB in Q2 2024 and has held it in 2 quarters since. The position peaked at $2.01M in Q2 2024. 67 funds tracked by Wall St. Rank hold INMB as of Q3 2024.

  • Raymond James Financial Services Advisors held 369,438 shares of INmune Bio worth $1.99M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 141,904 INmune Bio shares in Q3 2024, an estimated $1.01M.
  • INmune Bio made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1725 holding.
  • Raymond James Financial Services Advisors first reported a position in INmune Bio in Q2 2024 and has held it in 2 quarters since.
  • Raymond James Financial Services Advisors's INmune Bio position peaked at $2.01M in Q2 2024.
  • 67 funds tracked by Wall St. Rank held INmune Bio as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.